辅助生殖技术的使用和儿童癌症幸存者的结果
Kimberly W Keefe1, Andrea Lanes1, Kayla Stratton2
1Center for Infertility and Reproductive Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Cancer
|September 21, 2023
概括
儿童癌症幸存者与他们的兄弟姐妹相似,使用辅助生殖技术 (ART) 生育率相似. 放射治疗降低了ART的成功,但基剂暴露没有影响结果,为保护生育提供了指导.
科学领域:
- 生殖医学 生殖医学
- 在瘤学瘤学.
- 儿科瘤学 儿科瘤学
背景情况:
- 儿童癌症治疗,包括放射和化疗,可以减少幸存者的卵巢储备.
- 辅助生殖技术 (ART) 在妇女儿童癌症幸存者中实现活产的有效性尚未得到充分证实.
研究的目的:
- 评估与兄弟姐妹相比,儿童癌症幸存者的活产率和ART的成功率.
- 研究特定癌症治疗暴露 (辐射,基剂) 与幸存者的ART结果之间的关联.
主要方法:
- 一项队列研究将儿童癌症幸存者 (儿童癌症幸存者研究) 与国家ART数据 (辅助生殖技术协会临床结果报告系统) 联系起来.
- 使用概括估计方程来评估活产率,将幸存者与兄弟姐妹对照组进行比较.
- 为了确定与治疗暴露的关联,计算了相对风险 (RR) 和95%置信区间 (95%CI).
主要成果:
- 在9885名女性幸存者中,137人接受了ART,与兄弟姐妹相比,使用率相似 (1.4%).
- 使用自身卵子的幸存者每次卵巢刺激 (31.6%) 和每次移植 (43.9%) 的活产率与兄弟姐妹相比 (分别为38.3%和50.0%).
- 和盆腔辐射治疗与减少活产的可能性有关 (RR 0.44和0.33),而基剂暴露并没有显著影响结果 (RR 1.04).
结论:
- 儿童癌症幸存者表现出与兄弟对照相比的ART利用率和成功率.
- 在幸存者中,ART的成功并未因先前的基剂暴露而减弱.
- 这些发现为儿童癌症幸存者使用ART和生育咨询提供了关键指导.
相关概念视频
Bone Marrow Sampling and Transplants
352
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
352
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


